New Anti-VEGF Drugs in Ophthalmology
Claudio Campa
Abstract
This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.
Topics & Concepts
RanibizumabMedicineVEGF receptorsClinical trialPharmacologyInternal medicineBevacizumabChemotherapyRetinal Diseases and TreatmentsAngiogenesis and VEGF in CancerGlaucoma and retinal disorders